ReachMD Healthcare Image
Media formats available:
  • Overview

    Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoint in trials and the ongoing challenge of defining and measuring “clinically meaningful benefit” for patients with ATTR-CM. Don't miss this opportunity to gain valuable insights and elevate your understanding of ATTR-CM treatment strategies!

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Marianna Fontana, MD
    Director of the UCL CMR Unit, Royal Free Hospital
    Professor of Cardiology and Honorary Consultant Cardiologist
    National Amyloidosis Centre, Division of Medicine
    University College of London
    London, UK

    Dr. Fontana has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Akcea, Alexion, Alnylam, AstraZeneca, Attralus, Intellia, Ionis, Janssen, Novo Nordisk, Pfizer, Prothena​
    Research: Alnylam, Eidos, Pfizer

    Ronald Witteles, MD
    Professor of Cardiovascular Medicine
    Co-Director, Stanford Amyloid Center
    Stanford University School of Medicine
    Stanford, CA

    Dr. Witteles has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Alexion, Alnylam, AstraZeneca, BridgeBio, Novo Nordisk, Pfizer
    Research: Alnylam, BridgeBio, Ionis, Janssen, Pfizer

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard Green has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Collen Resnick has nothing to disclose. 
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.
    • Mario Trucillo, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the rationale for the design of recent clinical trials, considering the key findings and limitations of the previous trials in the management of amyloid transthyretin cardiomyopathy (ATTR-CM)
    • Analyze the role of diuretic use as an endpoint in ATTR-CM clinical trials, drawing on evidence from recent studies
    • Develop a framework for defining clinically meaningful benefit in ATTR-CM, considering functional capacity, symptom improvement, patient-reported outcomes, and disease progression   
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Alnylam Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free